BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35901358)

  • 1. Immunohistochemical Expression of Programmed Death Ligand 1(PDL1) in Endometrial Carcinoma and Its Relation to CD4 and CD8 Positive Immune Cells.
    Salama ME; Khairy DA
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2491-2496. PubMed ID: 35901358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.
    Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4
    Khalifa R; Elsese N; El-Desouky K; Shaair H; Helal D
    J Immunoassay Immunochem; 2022 Mar; 43(2):192-212. PubMed ID: 34697997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune parameters associated with survival in metaplastic breast cancer.
    Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
    Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
    Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
    Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of tumor-reactive CD4
    Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
    Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
    Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
    Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
    Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
    Chandrasekaran D; Sundaram S; N K; R P
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2951-2957. PubMed ID: 31653140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.
    Souza VG; Santos DJS; Silva AG; Ribeiro RIMA; Loyola AM; Cardoso SV; Miranda CSS; Cardoso LPV
    J Appl Oral Sci; 2022; 30():e20210344. PubMed ID: 35195152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
    Graeser M; Feuerhake F; Gluz O; Volk V; Hauptmann M; Jozwiak K; Christgen M; Kuemmel S; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kolberg-Liedtke C; Kates R; Wuerstlein R; Nitz U; Kreipe HH; Harbeck N
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.
    Igarashi T; Teramoto K; Ishida M; Hanaoka J; Daigo Y
    Oncol Rep; 2017 Oct; 38(4):2189-2196. PubMed ID: 28791392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
    Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
    Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L; Bodo J; Durkin L; Hsi ED
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.